v3.26.1
License and Collaboration Agreements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 14, 2025
Jan. 31, 2022
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
License And Collaboration Agreement [Line Items]              
Current deferred revenue     $ 8,523   $ 8,523   $ 11,901
Licensing Agreements              
License And Collaboration Agreement [Line Items]              
Percentage of development costs 70.00%            
Acadia Agreement              
License And Collaboration Agreement [Line Items]              
Receivables     1,800   1,800    
Current deferred revenue     4,300   4,300    
Revenue Recognized     2,800 $ 10,700 5,000 $ 16,800  
Biogen License Agreement              
License And Collaboration Agreement [Line Items]              
Receivables     5,400   5,400    
Consideration     9,800   9,800    
Current deferred revenue     4,200   4,200    
Revenue Recognized     $ 6,500 $ 3,200 10,563 $ 155,618  
Initial transaction price         243,400    
Non-refundable upfront payment         165,000    
Estimated variable consideration related to cost reimbursements for global development activities         $ 78,400    
Acadia Pharmaceuticals Inc.              
License And Collaboration Agreement [Line Items]              
Upfront Payment received   $ 60,000          
Potential milestone payments receivable   245,000          
Eligible milestone payments receivable   $ 662,500          
Agreement termination impact description         As a result of the termination of the Discontinued Acadia Programs, the Company is no longer eligible to receive the milestones for those programs of up to $662.5 million or any royalties related thereto.    
Biogen International GmbH | Licensing Agreements              
License And Collaboration Agreement [Line Items]              
Upfront Payment received $ 165,000            
Development milestone receivable 50,000            
Commercial milestone receivable $ 335,000            
Percentage of development costs 30.00%